Postexposure prophylaxis after nonoccupational HIV exposure: Clinical, ethical, and policy considerations

JAMA

Volumn 280, Issue 20, 1998, Pages 1769-1773

  Lurie, Peter ^a,d   Miller, Suellen ^e   Hecht, Frederick ^b   Chesney, Margaret ^a,c   Lo, Bernard ^a,c,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Public Citizen   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; ZIDOVUDINE;

ARTICLE; HEALTH CARE ACCESS; HEALTH ECONOMICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; OCCUPATIONAL EXPOSURE; PATIENT COMPLIANCE; POPULATION EXPOSURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; RAPE; RISK MANAGEMENT; SEROPREVALENCE; SEXUAL BEHAVIOR; SEXUAL TRANSMISSION;

EID: 0032567123     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.280.20.1769     Document Type: Article

References (60)

1. Emery T. AIDS drug cocktail finds growing role in preventing infection. Boston Globe. January 13, 1997:C1.
2. Sullivan A. When plagues end: notes on the twilight of an epidemic. New York Times Magazine. November 10, 1996:52-76, 77, 84.
3. Leland J. The end of AIDS: not yet, but new drugs offer hope. Newsweek. December 2, 1996:64-74.
4. Okie S. Should preventive HIV therapy be expanded? officials ponder using drugs after accidental sexual exposure to AIDS virus. Washington Post, February 4, 1997:Z13.
5. Painter K. Morning after: HIV experts worry it will erase preventive gains. USA Today. November 3, 1997:01.
6. Perlman D. Morning-after HIV experiment starts in S.F. project to offer drugs, counseling. San Francisco Chronicle. October 14, 1997:A2.
7. Centers for Disease Control and Prevention. Update: provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV. MMWR Morb Mortal Wkly Rep. 1996;45:468-472.
8. Katz MH, Gerberding JL. Postexposure treatment of people exposed to the human immunodeficiency virus through sexual contact or injection-drug use. N Engl J Med. 1997;336:1097-1100.
9. Beauchamp T, Childress J. Principles of Biomedical Ethics. 3rd ed. New York, NY: Oxford University Press; 1989.
10. Lo B. Resolving Ethical Dilemmas: A Guide for Clinicians. Baltimore, Md: Williams & Wilkins; 1995.
11. Katz MH, Gerberding JL. The care of persons with recent sexual exposure to HIV. Ann Intern Med. 1998;128:306-312.
12. Centers for Disease Control and Prevention. Case-control study of HIV seroconversion in health-care workers after percutaneous exposures to HIV-infected blood - France, United Kingdom and United States, January 1988-August 1994. MMWR Morb Mortal Wkly Rep. 1995;44:929-933.
13. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994;331:1173-1180.
14. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med. 1996;335:1621-1629.
15. Centers for Disease Control and Prevention. Administration of zidovudine during late pregnancy and delivery to prevent perinatal HIV transmission - Thailand, 1996-1998. MMWR Morb Mortal Wkly Rep. 1998;47:151-154.
16. Niu MT, Stein DS, Schnittman SM. Primary human immunodeficiency virus type 1 infection. J Infect Dis. 1993;168:1490-1501.
17. Basham T, Rios CD, Holdener T, Merigan TC. Zidovudine AZT reduces virus titer, retards immune dysfunction, and prolongs survival in the LP-BM5 murine induced immunodeficiency model. J Infect Dis. 1990;161:1006-1009.
18. Tsai CC, Follis KE, Sabo A. et al. Prevention of SIV infection in macaques by R-9-2-phosphonylme-thoxypropyl adenine. Science. 1995;270:1197-1199.
19. Centers for Disease Control and Prevention. National HIV Serosurveillance Summary: Update - 1993. Vol 3. Atlanta, Ga: US Dept of Health and Human Services; 1995.
20. Ippolito G, Puro V, De Carli G. the Italian Study Group on Occupational Risk of HIV Infection. The risk of occupational human immunodeficiency virus infection in health care workers: Italian Multicenter Study. Arch Intern Med. 1993;153:1451-1458.
21. DeGruttola V, Seage GRD, Mayer KH, Horsburgh CR Jr. Infectiousness of HIV between male homosexual partners. J Clin Epidemiol. 1989;42: 849-856.
22. Mastro TID. Probabilities of sexual HIV-1 transmission. AIDS. 1996;10(suppl A):S75-S82.
23. Padian NS, Shiboski SC, Jewell NP. Female-to-male transmission of human immunodeficiency virus. JAMA. 1991;266:1664-1667.
24. Seidlin M, Vogler M, Lee E, Lee YS, Dubin N. Heterosexual transmission of HIV in a cohort of couples in New York City. AIDS. 1993;7:1247-1254.
25. Craib KJ, Meddings DR, Strathdee SA, et al. Rectal gonorrhoea as an independent risk factor for HIV infection in a cohort of homosexual men. Genitourin Med. 1995;71:150-154.
26. Mayer KH, Anderson DJ. Heterosexual HIV transmission. Infect Agents Dis. 1995;4:273-284.
27. Padian NS, Abrams J, Skurnick JH, Van Devanter NL, O'Brien TR. Risk factors for postcoital bleeding among women with or at risk for infection with human immunodeficiency virus. J Infect Dis. 1995;172:1084-1087.
28. Royce RA, Seana A, Cates W Jr, Cohen MS. Sexual transmission of HIV. N Engl J Med. 1997; 336:1072-1078.
29. Kaplan EH, Heimer R. A model-based estimate of HIV infectivity via needle sharing. J Acquir Immune Defic Syndr. 1992;5:1116-1118.
30. Gaughwin MD, Gowans E, Ali R, Burrell C. Bloody needles: the volumes of blood transferred in simulations of needlestick injuries and shared use of syringes for injection of intravenous drugs. AIDS. 1991;5:1025-1027.
31. Holmberg SD. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health. 1996;86:642-654.
32. Montoya ID, Atkinson JS. Determinants of HIV seroprevalence rates among sites participating in a community-based study of drug users. J Acquir Immune Defic Syndr Human Retrovirol. 1996;13:169-176.
33. Gayle HD, Keeling RP, Garcia-Tunon M, et al. Prevalence of the human immunodeficiency virus among university students. N Engl J Med. 1990;323: 1538-1541.
34. Gostin LO, Lazzarini Z, Alexander D, Brandt AM, Mayer KH, Silverman DC. HIV testing, counseling, and prophylaxis after sexual assault. JAMA. 1994;271:1436-1444.
35. Rambow B, Adkinson C, Frost TH, Peterson GF. Female sexual assault: medical and legal implications. Ann Emerg Med. 1992;21:727-731.
36. National Victim Center. National Women's Study: Rape in America: A Report to the Nation. Arlington, Va: National Victim Center; 1992.
37. Ledray LE. Sexual assault nurse clinician. AWHONNS Clin Issues Perinat Womens Health Nurs. 1993;4:180-190.
38. Young WW, Bracken AC, Goddard MA, Matheson S. Sexual assault: review of a national model protocol for forensic and medical evaluation. Obstet Gynecol. 1992;80:878-883.
39. Catania JA, Kegeles SM, Coates TJ. Towards an understanding of risk behavior. Health Educ Q. 1990;17:53-72.
40. Fishbein M, Middlestadt S, Hitchcock P. Using information to change sexually transmitted disease-related behaviors. In: DiClemente RJ, Peterson JL, eds. Preventing AIDS: Theories and Methods of Behavioral Interventions. New York, NY: Plenum Press; 1994:61-78.
41. Rosenstock S, Edwards D, Tucker A. The health belief model and HIV risk behavior change. In: DiClemente RJ, Peterson JL, eds. Preventing AIDS: Theories and Methods of Behavioral Interventions. New York, NY: Plenum Press; 1994:5-24.
42. Dilley JW, Woods WJ, McFarland W. Are advances in treatment changing views about high-risk sex? N Engl J Med. 1997;337:501-502.
43. Bagshaw S, Edwards D, Tucker A. Ethinyl oestradiol and d-norgestrel is an effective emergency postcoital contraceptive. Aust N Z J Obstet Gynecol. 1988;28:137-140.
44. Ellertson C, Winikoff B, Armstrong E, Camp S, Senanayake P. Expanding access to emergency contraception in developing countries. Stud Fam Plann. 1995;26:251-263.
45. Smith LF, Whitfield MJ. Women's knowledge of taking oral contraceptive pills correctly and of emergency contraception. Br J Gen Pract. 1995;45:409-414.
46. Brown WF. Mayor's Summit on AIDS & HIV, Preliminary Report. San Francisco, Calif: Office of the Mayor; January 27, 1998.
47. Vanchieri C. Preparedness is key to treating HIV-exposed health care workers. Ann Intern Med. 1996;125:161-162.
48. Tokars JI, Marcus R, Culver DH, et al. Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood. Ann Intern Med. 1993;118:913-919.
49. Lipsky JJ. Antiretroviral drugs for AIDS. Lancet. 1996;348:800-803.
50. Singh N, Squier C, Sivek C, Wagener M, Nguyen MH, Yu VL. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus. AIDS Care. 1996;8:261-269.
51. Emini EA. Resistance to anti-human immunodeficiency virus therapeutic agents. Adv Exp Med Biol. 1995;390:187-195.
52. Chesney M, Folkman S. The psychosocial management of HIV disease. In: Holmes K, Sparling P, Mardh S, ed. Sexually Transmitted Diseases. 3rd ed. In press.
53. Freeman RC, Rodriguez GM, French JF. Compliance with AZT treatment regimen of HIV-seropositive injection drug users: a neglected issue. AIDS Educ Prev. 1996;8:58-71.
54. LeBlanc S, Sabados R, Howard D. Your Money or Your Life: Making a Killing on People With AIDS: An ACT UP Survey of Unconscionable AIDS Drug Pricing. San Francisco, Calif: AIDS Coalition to Unleash Power; 1996.
55. Li RW, Wong J. Postexposure treatment of HIV. N Engl J Med. 1997;337:499-500.
56. Pinkerton SD, Holtgrave DR, Bloom FR. Post-exposure treatment of HIV. N Engl J Med. 1997; 337:500-501.
57. Fabian R. The Qualy approach. In: Tolley GS, Kenkel DS, Fabian RG, eds. Valuing Health for Policy: An Economic Approach. Chicago, Ill: University of Chicago Press; 1994:118-136.
58. Martin JN, Coates TJ, Roland ME, et al. Post-exposure prevention (PEP) of HIV folio wing sexual or drug use exposure: the role of source partner information in determining true HIV exposure. Paper presented at: 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26, 1998; San Diego, Calif.
59. Centers for Disease Control and Prevention. Public Health Service guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis. MMWR Morb Mortal Wkly Rep. 1998;47(No. RR-7):1-34.
60. Centers for Disease Control and Prevention. Management of possible sexual, injection-drug-use, or other nonoccupational exposure to HIV, including considerations related to antiretroviral therapy: Public Health Service Statement. MMWR Morb Mortal Wkly Rep. 1998;47(No. RR-17):1-14.